Naslov
Evaluation the virological response and side effects during the treatment with peginterferon alfa-2a alone or in combination with ribavirin in chronic hepatitis C (CHC). Croatian study

Autori
Hrstić, Irena ; Vucelić, Boris ; Ostojić, Rajko ; Vince, A ; Bradarić, N ; Štimac, Davor ; Včev, A ; Miše, S ; Morović, M ;

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
4th Central European Gastroenterology Meeting (CEURGEM) / - , 2006, 30-30

Skup
4th Central European Gastroenterology Meeting (CEURGEM)

Mjesto i datum
Visegrád, Mađarska, 29.06.2006. - 02.07.2006

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
Chronic hepatitis C; peginterferon alfa-2a; ribavirin; virological response; side effects

Sažetak
Aim: To evaluate the efficacy and safety of peginterferon alfa-2a (180 μ g/week) alone and in combination with ribavirin (800 mg/day) in Croatian CHC patients were genotype 1b has the highest prevalence. Patients and methods: 87 initial study patients (53 M, 34 F, mean age 40, 2) with histologically proven CHC are analysed. HCV RNA (PCR) was determined after 12 weeks. Patients with detectable viremia were excluded. Primary goal was to determine the end-of-treatment response (ETR) and the second was to determine the side effects. Group A, 14 naive patients treated with peginterferon alfa-2a monotherapy for 48 weeks. Group B, 28 naive patients treated with combination therapy for 24 weeks. Group C, 45 patients treated with combination therapy for 48 weeks. Serum HCV RNA clearance was considered as virological response. Results: Group A: at week 12, seven patients were excluded. Remaining 6 patients (42, 9%) had ETR. Group B: ETR at week 24 was 75, 0% (21/28). Group C: ETR at week 48 was 68, 9% (31/45). At least one non serious adverse event was notice in overall 19, 5% patients. Trombocytopenia was the most one observed, especially in group A. One patients experienced the serious adverse event, diabetes mellitus, which lead to treatment discontinuation. Conclusion: Overall virological response achieved on treatment with peginterferon alfa-2a was excellent even in the monotherapy group of patients. The best results were observed in patients treated with combination therapy for 48 weeks. Non serious adverse events can be expected in minor group patients. This study was sponsored by Roche, Croatia.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA